Fulcrum Therapeutics, Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Fulcrum is a clinical-stage biotechnology company developing treatments for genetically defined rare diseases. This unaudited filing covers the three months ended March 31, 2022; balance-sheet comparisons are with December 31, 2021. Its two clinical-stage candidates are losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for sickle cell disease and other hemoglobinopathies. The company had no product sales.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Collaboration revenue | $2.6 million | $4.8 million |
| Research and development expense | $17.8 million | $16.3 million |
| General and administrative expense | $10.8 million | $5.5 million |
| Operating loss | $26.0 million | $17.0 million |
| Net loss | $25.9 million | $17.0 million |
| Basic and diluted net loss per share | $0.64 | $0.54 |
| Net cash used in operating activities | $22.1 million | $16.2 million |
Cash, cash equivalents and marketable securities totaled $195.1 million at March 31, 2022, down from $218.2 million at year-end 2021. The company reported total current assets of $200.1 million and current liabilities of $18.3 million. It had no reported borrowings; operating lease liabilities totaled $15.2 million, including $2.4 million current. Accumulated deficit was $328.4 million. Operating margins are not a useful measure for this pre-revenue development-stage business.
Material changes versus the prior comparable period
- Revenue declined $2.2 million, reflecting lower collaboration revenue: Acceleron revenue fell from $2.6 million to $0.9 million, while MyoKardia revenue declined from $2.2 million to $1.7 million.
- R&D expense rose $1.5 million, principally from higher employee compensation and increased FTX-6058 external development costs; lower losmapimod external costs partly offset the increase.
- G&A expense increased $5.3 million, mainly due to higher compensation, professional services and preparatory commercial activities.
- Net loss widened by $8.9 million. Operating cash use increased $5.9 million. Q1 2021 financing included $47.4 million of net proceeds from a public offering; Q1 2022 financing was mainly employee-plan stock proceeds.
- On January 1, 2022, the company adopted lease accounting Topic 842 and recorded right-of-use assets and lease liabilities. Management said adoption did not materially affect the income statement or cash flows.
Outlook, management commentary, risks and unusual items
- Management said existing cash, cash equivalents and marketable securities were expected to fund operating expenses and capital needs into 2024. The estimate depends on assumptions and could prove shorter; the company expects continuing losses and says additional financing will be needed.
- At the filing date, the company expected to initiate the Phase 3 REACH trial of losmapimod in Q2 2022; planned to present initial FTX-6058 Phase 1b sickle-cell data at the June 2022 EHA congress; and expected to start a Phase 1b trial in other hemoglobinopathies, including beta-thalassemia, in the second half of 2022. It also expected to nominate another development candidate in 2022 and support a fourth IND by the end of Q1 2023. These are forward-looking plans, not reported outcomes.
- Key risks include clinical-trial safety, efficacy, enrollment and timing; regulatory uncertainty and novel endpoints; COVID-19-related operational or supply disruption; reliance on CROs and contract manufacturers; competition; intellectual-property protection; and dependence on future financing and collaboration performance.
- The filing highlights that GSK-licensed losmapimod composition-of-matter patents were expected to expire February 10, 2023; other patent rights may remain, but the expiration could reduce protection for uses not covered by those rights.
- Marketable securities had $1.1 million of unrealized losses at quarter-end, recorded in other comprehensive loss; management reported no other-than-temporary impairment and no intent or expected requirement to sell before recovery. The filing reported no material legal proceedings or accrued indemnification liabilities.
- Disclosure controls and procedures were assessed as effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether the REACH Phase 3 trial and planned FTX-6058 studies began on schedule, and what subsequent clinical data showed.
- Whether collaboration receipts and milestone prospects can offset a portion of increasing development costs, and whether additional financing is needed before the stated runway into 2024.
- How cash burn, investment maturities and lease obligations affect liquidity; the filing reports operating cash use of $22.1 million for the quarter.
- The status and scope of losmapimod patent protection after the disclosed February 2023 composition-of-matter patent expiration.
- Whether trial endpoints, manufacturing supply, enrollment, regulatory requirements or collaboration partner priorities change development timelines or costs.